Dr Shreyas Kalantri speaks to ecancer about evaluation of quality of life endpoint planning and reporting in phase III genitourinary oncology randomised controlled trials.

He explains that his study examined phase III randomised controlled trials in genitourinary cancers published from 2020 to 2024 to assess how often quality-of-life outcomes, though prospectively planned, were actually reported.

Among 79 trials, only 41 percent included quality-of-life results, and over a third of trials that had planned these assessments failed to publish them.

Trials with positive efficacy results were three times more likely to report quality-of-life outcomes than negative trials, while publication in high-impact journals also increased reporting.

These findings highlight the need for greater transparency and consistent adherence to prespecified patient-reported outcome measures in genitourinary oncology studies.